Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin Apotheke
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Spektrum der Augenheilkunde
Erschienen in: Spektrum der Augenheilkunde 1/2024

13.07.2023 | Augenheilkunde | DFP-Fortbildung Zur Zeit gratis

Antikoagulation und Thrombozytenfunktionshemmung

Was in der augenärztlichen Praxis zu beachten ist

verfasst von: Prof. Dr. med. Oliver Zeitz, Laura Wernecke, Nicolas Feltgen, Christoph Sucker, Jürgen Koscielny, Thomas Dörner

Erschienen in: Spektrum der Augenheilkunde | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Zusammenfassung

Viele Augenerkrankungen, die eine operative Intervention erfordern, sind Erkrankungen des älteren Menschen. Daher bestehen häufig internistische Komorbiditäten. In deren Behandlung spielt in vielen Fällen die medikamentöse Hemmung der Blutgerinnung eine wichtige Rolle. Es gibt verschiedene Möglichkeiten, die Blutgerinnung pharmakologisch zu beeinflussen, wobei die Zahl der Optionen in den letzten Jahren durch die Einführung neuer Medikamente zugenommen hat. Der Beitrag bietet einen Überblick darüber, welche Möglichkeiten es heute gibt, die Blutgerinnung therapeutisch zu hemmen, und warum dies aus internistischer Sicht wichtig ist. Daneben werden die Grundzüge der Therapiesteuerung dargestellt. Des Weiteren wird die pharmakologische Hemmung der Blutgerinnung im Kontext mit Augenoperationen erörtert. Insbesondere wird die verfügbare Literatur im Hinblick auf die Notwendigkeit, die Therapie mit Gerinnungshemmern für Augenoperationen zu unterbrechen oder umzustellen, analysiert.
Vorheriger Artikel Retinoblastom Report Österreich 2021
Literatur
1.
Cohen AT, Spiro TE, Buller HR et al (2013) Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 368:513–523PubMedCrossRef
2.
Goldhaber SZ, Leizorovicz A, Kakkar AK et al (2011) Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 365:2167–2177PubMedCrossRef
3.
Alexander JH, Lopes RD, James S et al (2011) Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 365:699–708PubMedCrossRef
4.
Lum DJ, Ross PA, Bishop MA et al (2017) Evaluation of a standardized perioperative management protocol in the adult hematology anticoagulation management service. Ann Pharmacother 51:1077–1083PubMedCrossRef
5.
6.
Gurbel PA, Tantry US (2014) Antiplatelet and anticoagulant agents in heart failure: current status and future perspectives. JACC Heart Fail 2:1–14PubMedCrossRef
7.
8.
Lettau M, Schrezenmeier EV, Specker C et al (2020) Lupus and thrombophilia : antiphospholipid syndrome. Z Rheumatol 79:332–341PubMedCrossRef
9.
Tektonidou MG, Andreoli L, Limper M et al (2019) EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 78:1296–1304PubMedCrossRef
10.
Werth S, Breslin T, Niainle F et al (2015) Bleeding risk, management and outcome in patients receiving non-VKA oral anticoagulants (NOAcs). Am J Cardiovasc Drugs 15:235–242PubMedCrossRef
11.
Roffi M, Patrono C, Collet JP et al (2016) 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). G Ital Cardiol 17:831–872
12.
Steg PG, James SK, Atar D et al (2012) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33:2569–2619PubMedCrossRef
13.
Anonymous (Stand 1018) Fachinformation Brilique® 90 mg/60 mg.
14.
Anonymous (Stand 2019) Fachinformation Efient®.
15.
Anonymous (Stand 2018) Fachinformation Plavix®.
16.
17.
Korte W, Cattaneo M, Chassot PG et al (2011) Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on Perioperative Coagulation of the Austrian Society for Anesthesiology, Resuscitation and Intensive Care (ÖGARI) and the Working Group Thrombosis of the European Society for Cardiology (ESC). Thromb Haemost 105:743–749PubMedCrossRef
18.
Zeymer U, Koscielny J, Von Heymann C et al (2016) Bleeding in patients receiving dual antiplatelet therapy after acute coronary syndrome—significance, prevention and interdisciplinary management. Dtsch Med Wochenschr 141:1107–1111PubMed
19.
Gurbel PA, Bliden KP, Butler K et al (2009) Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120:2577–2585PubMedCrossRef
20.
Oprea AD, Popescu WM (2013) Perioperative management of antiplatelet therapy. Br J Anaesth 111(Suppl 1):i3–i17PubMedCrossRef
21.
Fleisher LA, Fleischmann KE, Auerbach AD et al (2014) 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 64:e77–e137PubMedCrossRef
22.
Koscielny J, Von Heymann C, Zeymer U et al (2017) Dual antiplatelet therapy in the perioperative period—to continue or discontinue treatment? Dtsch Med Wochenschr 142:1223–1230PubMed
23.
Frontera JA, Lewin JJ, Rabinstein AA et al (2016) Guideline for reversal of antithrombotics in Intracranial hemorrhage: a statement for healthcare professionals from the neurocritical care society and society of critical care medicine. Neurocrit Care 24:6–46PubMedCrossRef
24.
Hindricks G, Potpara T, Dagres N et al (2021) 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 42:373–498PubMedCrossRef
25.
Calenda E, Cardon-Guiton A, Genevois O et al (2011) Peribulbar block in 500 patients scheduled for eye procedures and treated with acetyl salicylic acid. Acta Anaesthesiol Taiwan 49:141–143PubMedCrossRef
26.
Calenda E, Genevois O, Cardon A et al (2014) Peribulbar anesthesia in 750 patients treated with oral anticoagulants. Int J Ophthalmol 7:110–113PubMedPubMedCentral
27.
Calenda E, Lamothe L, Genevois O et al (2012) Peribulbar block in patients scheduled for eye procedures and treated with clopidogrel. J Anesth 26:779–782PubMedCrossRef
28.
Huebert I, Heinicke N, Kook D et al (2015) Dual platelet inhibition in cases of severe retrobulbar hemorrhage following retrobulbar and peribulbar anesthesia. J Cataract Refract Surg 41:2092–2101PubMedCrossRef
29.
Shin YI, Sung JY, Sagong M et al (2018) Risk factors for breakthrough vitreous hemorrhage after intravitreal anti-VEGF injection in age-related macular degeneration with submacular hemorrhage. Sci Rep 8:10560PubMedPubMedCentralCrossRefADS
30.
Feltgen N, Mele B, Dietlein T et al (2018) Management of anticoagulants in ophthalmic surgery—a survey among ophthalmic surgeons in Germany. Ophthalmologe 115:585–591PubMedCrossRef
31.
Cheung JJC, Liu S, Li KKW (2019) Phacoemulsification cataract surgery in patients receiving novel oral anticoagulant medications. Int Ophthalmol 39:623–630PubMedCrossRef
32.
Grzybowski A, Ascaso FJ, Kupidura-Majewski K et al (2015) Continuation of anticoagulant and antiplatelet therapy during phacoemulsification cataract surgery. Curr Opin Ophthalmol 26:28–33PubMedCrossRef
33.
Katz J, Feldman MA, Bass EB et al (2003) Risks and benefits of anticoagulant and antiplatelet medication use before cataract surgery. Ophthalmology 110:1784–1788PubMedCrossRef
34.
Kiire CA, Mukherjee R, Ruparelia N et al (2014) Managing antiplatelet and anticoagulant drugs in patients undergoing elective ophthalmic surgery. Br J Ophthalmol 98:1320–1324PubMedCrossRef
35.
Douketis JD, Spyropoulos AC, Spencer FA et al (2012) Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 141:e326S–e350SPubMedPubMedCentralCrossRef
36.
Kristensen SD, Knuuti J, Saraste A et al (2014) 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol 31:517–573PubMedCrossRef
37.
Jeganathan VS, Ghosh S, Ruddle JB et al (2008) Risk factors for delayed suprachoroidal haemorrhage following glaucoma surgery. Br J Ophthalmol 92:1393–1396PubMedCrossRef
38.
Sozeri Y, Salim S (2018) Anticlotting agents and the surgical management of glaucoma. Curr Opin Ophthalmol 29:185–189PubMedCrossRef
39.
Cobb CJ, Chakrabarti S, Chadha V et al (2007) The effect of aspirin and warfarin therapy in trabeculectomy. Eye (Lond) 21:598–603PubMedCrossRef
40.
Law SK, Song BJ, Yu F et al (2008) Hemorrhagic complications from glaucoma surgery in patients on anticoagulation therapy or antiplatelet therapy. Am J Ophthalmol 145:736–746PubMedCrossRef
41.
Widder RA, Lappas A, Rennings C et al (2020) Influence of oral anticoagulation on success rates and risk of bleeding events after iStent inject implantation combined with phacoemulsification. Graefes Arch Clin Exp Ophthalmol 258:2483–2487
42.
Bemme S, Lauermann P, Striebe NA et al (2020) Risk of perioperative bleeding complications in rhegmatogenous retinal detachment surgery: a retrospective single-center study. Graefes Arch Clin Exp Ophthalmol 258:961–969PubMedCrossRef
43.
44.
45.
Dayani PN, Grand MG (2006) Maintenance of warfarin anticoagulation for patients undergoing vitreoretinal surgery. Trans Am Ophthalmol Soc 104:149–160PubMedPubMedCentral
46.
Meillon C, Gabrielle PH, Bron AM et al (2019) Antiplatelet and anticoagulant agents in vitreoretinal surgery: a prospective multicenter study involving 804 patients. Graefes Arch Clin Exp Ophthalmol 257:427PubMedCrossRef
47.
Oh J, Smiddy WE, Kim SS (2011) Antiplatelet and anticoagulation therapy in vitreoretinal surgery. Am J Ophthalmol 151:934–939.e3PubMedCrossRef
48.
Fabinyi DC, O’neill EC, Connell PP et al (2011) Vitreous cavity haemorrhage post-vitrectomy for diabetic eye disease: the effect of perioperative anticoagulation and antiplatelet agents. Clin Experiment Ophthalmol 39:878–884PubMedCrossRef
49.
Brown JS, Mahmoud TH (2011) Anticoagulation and clinically significant postoperative vitreous hemorrhage in diabetic vitrectomy. Retina 31:1983–1987PubMedCrossRef
50.
Patel R, Charles S, Jalil A (2017) Antiplatelets and anticoagulants in vitreoretinal surgery, with a special emphasis on novel anticoagulants: a national survey and review. Graefes Arch Clin Exp Ophthalmol 255:1275–1285PubMedCrossRef
51.
Hass AN, Penne RB, Stefanyszyn MA et al (2004) Incidence of postblepharoplasty orbital hemorrhage and associated visual loss. Ophthalmic Plast Reconstr Surg 20:426–432PubMedCrossRef
52.
Mejia JD, Egro FM, Nahai F (2011) Visual loss after blepharoplasty: incidence, management, and preventive measures. Aesthet Surg J 31:21–29PubMedCrossRef
53.
Custer PL, Trinkaus KM (2002) Hemorrhagic complications of oculoplastic surgery. Ophthalmic Plast Reconstr Surg 18:409–415PubMedCrossRef
54.
Esparaz ES, Sobel RK (2015) Perioperative management of anticoagulants and antiplatelet agents in oculoplastic surgery. Curr Opin Ophthalmol 26:422–428PubMedCrossRef
55.
Ing E, Douketis J (2014) New oral anticoagulants and oculoplastic surgery. Can J Ophthalmol 49:123–127PubMedCrossRef
56.
Kraft CT, Bellile E, Baker SR et al (2015) Anticoagulant complications in facial plastic and reconstructive surgery. JAMA Facial Plast Surg 17:103–107PubMedCrossRef
57.
Makuloluwa AK, Tiew S, Briggs M (2019) Peri-operative management of ophthalmic patients on anti-thrombotic agents: a literature review. Eye (Lond) 33:1044–1059PubMedCrossRef
58.
Robbins SL, Wang JW, Frazer JR et al (2019) Anticoagulation: a practical guide for strabismus surgeons. J AAPOS 23:193–199PubMedCrossRef
59.
60.
Arès C, Superstein R (2006) Retrobulbar hemorrhage following strabismus surgery. J AAPOS 10:594–595PubMedCrossRef
61.
Kemp PS, Larson SA, Drack AV (2014) Strabismus surgery in patients receiving warfarin anticoagulation. J AAPOS 18:84–86PubMedCrossRef
62.
Kuhli-Hattenbach C, Miesbach W, Scharrer I et al (2012) Massive subretinal hemorrhage and anticoagulants. An unfortunate combination? Ophthalmologe 109:665–669PubMedCrossRef
63.
Ying GS, Maguire MG, Daniel E et al (2016) Association between antiplatelet or anticoagulant drugs and retinal or subretinal hemorrhage in the comparison of age-related macular degeneration treatments trials. Ophthalmology 123:352–360PubMedCrossRef
64.
Azar G, Mauget-Faysse M, Nyouma J et al (2015) Occurrence of macular hematoma after ranibizumab treatment for age-related macular degeneration. Eur J Ophthalmol 25:163–167PubMedCrossRef
65.
Buitendijk GHS, Schauwvlieghe AME, Vingerling JR et al (2018) Antiplatelet and anticoagulant drugs do not affect visual outcome in neovascular age-related macular degeneration in the BRAMD trial. Am J Ophthalmol 187:130–137PubMedCrossRef
66.
El-Sanhouri AA, Foster RE, Petersen MR et al (2011) Retinal tears after posterior vitreous detachment and vitreous hemorrhage in patients on systemic anticoagulants. Eye (Lond) 25:1016–1019PubMedCrossRef
67.
Jun JH, Hwang JC (2015) Association of rivaroxaban anticoagulation and spontaneous vitreous hemorrhage. JAMA Ophthalmol 133:1184–1186PubMedCrossRef
Metadaten
Titel
Antikoagulation und Thrombozytenfunktionshemmung
Was in der augenärztlichen Praxis zu beachten ist
verfasst von
Prof. Dr. med. Oliver Zeitz
Laura Wernecke
Nicolas Feltgen
Christoph Sucker
Jürgen Koscielny
Thomas Dörner
Publikationsdatum
13.07.2023
Verlag
Springer Vienna
Erschienen in
Spektrum der Augenheilkunde / Ausgabe 1/2024
Print ISSN: 0930-4282
Elektronische ISSN: 1613-7523
DOI
https://doi.org/10.1007/s00717-023-00537-0

Weitere Artikel der Ausgabe 1/2024

Spektrum der Augenheilkunde 1/2024 Zur Ausgabe

original article

A comparative study on the use of fibrin glue versus sutures in pterygium surgery with conjunctivolimbal autograft and its impact on higher-order aberrations

review article

The clinical importance of uveomeningeal syndromes

originalarbeit

Retinoblastom Report Österreich 2021

case report

Early-onset sarcoidosis with R334Q mutation in the NOD2 gene

review

Diagnostic and therapeutic considerations in pediatric uveitis

14.07.2023 | Sammlung

Das könnte Sie auch interessieren

Bildnachweise